
Jing Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1285039/publications.pdf Version: 2024-02-01



LINC WANC

#	Article	IF	CITATIONS
1	Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers. Cancer Chemotherapy and Pharmacology, 2022, 89, 141-148.	2.3	4
2	TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-11 [±] degradation. Journal of Experimental and Clinical Cancer Research, 2022, 41, 44.	8.6	25
3	An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 683-695.	2.3	6
4	<i>ZNF582</i> promoter methylation predicts cervical cancer radiosensitivity and ZNF582 protein overexpression reduces radiosensitivity by cell cycle arrest in S phase. Epigenetics, 2022, 17, 1786-1799.	2.7	1
5	Development of a novel transcription factors-related prognostic signature for serous ovarian cancer. Scientific Reports, 2021, 11, 7207.	3.3	8
6	PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biology, 2021, 42, 101928.	9.0	150
7	Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer. Journal of Central South University (Medical Sciences), 2021, 46, 644-652.	0.1	0
8	Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. Modern Pathology, 2020, 33, 29-37.	5.5	28
9	Circular RNA circTNPO3 Regulates Paclitaxel Resistance of Ovarian Cancer Cells by miR-1299/NEK2 Signaling Pathway. Molecular Therapy - Nucleic Acids, 2020, 21, 780-791.	5.1	49
10	PARP inhibitor resistance: the underlying mechanisms and clinical implications. Molecular Cancer, 2020, 19, 107.	19.2	235
11	Comparison of survival outcomes of neoadjuvant therapy and direct surgery in IB2/IIA2 cervical adenocarcinoma: a retrospective study. Archives of Gynecology and Obstetrics, 2020, 301, 1247-1255.	1.7	7
12	TRPM7 promotes the epithelial–mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling. Journal of Experimental and Clinical Cancer Research, 2019, 38, 106.	8.6	90
13	Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Research, 2018, 78, 742-757.	0.9	98
14	TRPM7 is required for ovarian cancer cell growth, migration and invasion. Biochemical and Biophysical Research Communications, 2014, 454, 547-553.	2.1	48
15	Overexpression of TRPM7 is Associated with Poor Prognosis in Human Ovarian Carcinoma. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3955-3958.	1.2	27